
Becton Dickinson company profile
$218.03+1.08%Close 13 Nov 2026 · Market value $59.20B
About Becton Dickinson
Becton, Dickinson and Company (BD) is a global medical technology company that develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Its customers include healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies and the general public. Its product lines span medication management and infusion systems, prefillable drug delivery systems, advanced patient monitoring, specimen collection, infectious disease diagnostics, cell analysis reagents and instruments, and vascular, urology and surgical specialty products. BD manufactures and sells its products worldwide, with manufacturing operations in 18 countries outside the United States and sales organized across EMEA, Greater Asia, Latin America and Canada, in addition to the United States.
A summary of the business section of the company's latest annual report, filed 25 Nov 2025.
Company facts
| Ticker | BDX · NYSE |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 30 September |
|---|
| Reporting currency | USD |
|---|
| CIK | 10795 |
|---|
| Latest annual report | 10-K, filed 25 Nov 2025 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Thomas E. Polen | Chairman, CEO and President · Director | 528K · < 1% | Disposition to the issuer, 13 Aug 2026 |
|---|
| Michael D. Garrison | EVP & Pres Med.Essntl&BioPharm | 87.6K · < 1% | Sale under a 10b5-1 plan, 24 Jun 2026 |
|---|
| Richard E. Byrd | EVP & President Interventional | 83.1K · < 1% | Shares withheld for tax, 26 Nov 2025 |
|---|
| Christopher J. DelOrefice | EVP & Chief Financial Officer | 65.7K · < 1% | Shares withheld for tax, 26 Nov 2025 |
|---|
| Timothy M. Ring | Director | 60.1K · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Bertram L. Scott | Director | 54.2K · < 1% | Open-market sale, 18 Feb 2026 |
|---|
| Christopher Jones | Director | 34.2K · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Claire M. Fraser, Ph.D. | Director | 22.6K · < 1% | Open-market sale, 10 Sep 2025 |
|---|
| Catherine M. Burzik | Director | 14.9K · < 1% | Grant or award, 28 Jan 2025 |
|---|
| R. Andrew Eckert | Director | 9.3K · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Jeffrey W. Henderson | Director | 8.0K · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Gregory J. Hayes | Director | 6.1K · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Carrie L. Byington, M.D. | Director | 5.5K · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Michael C. Feld | EVP, Chief Revenue Officer | 4.1K · < 1% | Sale under a 10b5-1 plan, 28 Sep 2026 |
|---|
| William M. Brown | Director | 3.5K · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Joanne Waldstreicher, M.D. | Director | 2.3K · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Robert L. Huffines | Director | 180 · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Jacqueline Wright | Director | 180 · < 1% | Grant or award, 27 Jan 2026 |
|---|
| Roque Vitor | EVP & Chief Financial Officer | — | Shares withheld for tax, 2 Sep 2026 |
|---|
| Goette Roland | EVP and President, EMEA | — | Open-market sale, 11 Aug 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
BDX in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.